Skip to main content
Erschienen in: World Journal of Surgery 4/2018

25.09.2017 | Original Scientific Report

Influence of Pleurectomy and Decortication in Health-Related Quality of Life Among Patients with Malignant Pleural Mesothelioma

verfasst von: Wickii T. Vigneswaran, Diana Y. Kircheva, Adrian E. Rodrigues, Sydeaka Watson, Amy Durkin Celauro, Berkley Rose, Hedy L. Kindler, Aliya N. Husain

Erschienen in: World Journal of Surgery | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

Complete macroscopic resection surgery, pleurectomy and decortication (PD) improve survival in selected patients with malignant pleural mesothelioma (MPM). Yet its value has been questioned because of concern that this extensive surgical procedure may disrupt health-related quality of life (HRQoL).

Methods

HRQoL was studied in patients undergoing PD surgery for MPM using EORTC QLQ-C30 instrument at baseline (prior to surgery), 1, 4–5, 7–8, and 10–11 months following surgery. Global health and variables in function and symptom domains were investigated. Sub-groups analyses were performed for ECOG performance status (PS), histological sub-types and pathological tumor volume (pTV). Within-patient comparisons to baseline scores were made using Wilcoxon signed-rank test. Trends over time were evaluated using Cuzick’s nonparametric test.

Results

There were 114 patients with median age of 70 years (range: 50–88) and PS 0: 35 (30.7%), epithelioid histology: 61 (53.5%) and volume <600 ml: 58 (50.9%). Patients with good PS (PS 0), epithelioid histology and small pTV had greater level of functioning and were less symptomatic at baseline. Overall global health worsened at the first postoperative month (p = 0.0005) with subsequent improvement. Non-epithelioid histology and patients with large pTV demonstrated greater improvement in global health, function and symptoms domains following a PD.

Conclusions

At baseline, the overall health-related quality of life, function and symptom domains were adversely affected in non-epithelioid histology and patients with large pTV. However, greatest improvement in global health, symptom and function domains were observed first month after PD and during the follow-up in these sub-groups.
Literatur
1.
Zurück zum Zitat Betta PG, Magnani C, Bensi T et al (2012) Immunohistochemistry and molecular diagnostics of pleural malignant mesothelioma. Arch Pathol Lab Med 136(253):261 Betta PG, Magnani C, Bensi T et al (2012) Immunohistochemistry and molecular diagnostics of pleural malignant mesothelioma. Arch Pathol Lab Med 136(253):261
2.
Zurück zum Zitat Elliot W, Kammerstern M, Churg J (1983) Tumors and pseudotumors of the serous membranes. In: Atlas of tumor pathology. Second series, fascicle 20. Armed Forces Institute of Pathology, Washington, DC Elliot W, Kammerstern M, Churg J (1983) Tumors and pseudotumors of the serous membranes. In: Atlas of tumor pathology. Second series, fascicle 20. Armed Forces Institute of Pathology, Washington, DC
3.
Zurück zum Zitat Hillerdal G (1983) Malignant mesothelioma 1982: review of 4710 published cases. Br J Dis Chest 77:321–343CrossRefPubMed Hillerdal G (1983) Malignant mesothelioma 1982: review of 4710 published cases. Br J Dis Chest 77:321–343CrossRefPubMed
4.
Zurück zum Zitat Rusch VW, Giroux D (2012) Do we need a revised staging system for malignant pleural mesothelioma? Analysis of the IASLC database. Ann Cardiothorac Surg 1(4):438.48PubMed Rusch VW, Giroux D (2012) Do we need a revised staging system for malignant pleural mesothelioma? Analysis of the IASLC database. Ann Cardiothorac Surg 1(4):438.48PubMed
5.
Zurück zum Zitat Curran D, Sahmoud T, Therasse P, van Meerbeeck J, Postmus PE, Giaccone G (1998) Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol 16(145):52 Curran D, Sahmoud T, Therasse P, van Meerbeeck J, Postmus PE, Giaccone G (1998) Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol 16(145):52
6.
Zurück zum Zitat Pass HI, Giroux D, Kennedy C, Ruffini E, Cangir AK, Rice D, Asamura H, Waller D, Edwards J, Weder W, Hoffmann H, van Meerbeeck JP, Rusch VW (2014) Supplementary prognostic variables for pleural mesothelioma a report from the IASLC Staging Committee. J Thorac Oncol 9(6):856.64CrossRefPubMed Pass HI, Giroux D, Kennedy C, Ruffini E, Cangir AK, Rice D, Asamura H, Waller D, Edwards J, Weder W, Hoffmann H, van Meerbeeck JP, Rusch VW (2014) Supplementary prognostic variables for pleural mesothelioma a report from the IASLC Staging Committee. J Thorac Oncol 9(6):856.64CrossRefPubMed
7.
Zurück zum Zitat Taioli E, Wolf AS, Flores RM (2015) Meta-analysis of survival after pleurectomy decortication versus extrapleural pneumonectomy in mesothelioma. Ann Thorac Surg 99:472–481CrossRefPubMed Taioli E, Wolf AS, Flores RM (2015) Meta-analysis of survival after pleurectomy decortication versus extrapleural pneumonectomy in mesothelioma. Ann Thorac Surg 99:472–481CrossRefPubMed
8.
Zurück zum Zitat Flores RM, Pass HI, Seshan VE, Dycoco J, Zakowski M, Carbone M et al (2008) Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg 135(3):620–626CrossRefPubMed Flores RM, Pass HI, Seshan VE, Dycoco J, Zakowski M, Carbone M et al (2008) Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg 135(3):620–626CrossRefPubMed
9.
Zurück zum Zitat Burt BM, Cameron RB, Mollberg NM, Kosinski AS, Schipper PH, Shrager JB, Vigneswaran WT (2014) Malignant pleural mesothelioma and the society of thoracic surgeons database: an analysis of surgical morbidity and mortality. J Thorac Cardiovasc Surg 148(1):30.5PubMed Burt BM, Cameron RB, Mollberg NM, Kosinski AS, Schipper PH, Shrager JB, Vigneswaran WT (2014) Malignant pleural mesothelioma and the society of thoracic surgeons database: an analysis of surgical morbidity and mortality. J Thorac Cardiovasc Surg 148(1):30.5PubMed
10.
Zurück zum Zitat Mollberg NM, Vigneswaran Y, Kindler HL et al (2012) Quality of life after radical pleurectomy decortication for malignant pleural mesothelioma. Ann Thorac Surg 94:1086–1092CrossRefPubMed Mollberg NM, Vigneswaran Y, Kindler HL et al (2012) Quality of life after radical pleurectomy decortication for malignant pleural mesothelioma. Ann Thorac Surg 94:1086–1092CrossRefPubMed
11.
Zurück zum Zitat Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A (2001) EORTC QLQ-C30 scoring manual, 3rd edn. on behalf of the EORTC Quality of Life Group. Brussels: EORTC. ISBN: 2-9300 64-22-6 Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A (2001) EORTC QLQ-C30 scoring manual, 3rd edn. on behalf of the EORTC Quality of Life Group. Brussels: EORTC. ISBN: 2-9300 64-22-6
12.
Zurück zum Zitat Rice D, Rusch V, Pass H, Asamura H, Nakano T, Edwards J et al (2011) Recommendations for uniform definitions of surgical techniques for malignant pleural mesothelioma: a consensus report of the international association for the study of lung cancer international staging committee and the international mesothelioma interest group. J Thorac Oncol 6(8):1304.12CrossRefPubMed Rice D, Rusch V, Pass H, Asamura H, Nakano T, Edwards J et al (2011) Recommendations for uniform definitions of surgical techniques for malignant pleural mesothelioma: a consensus report of the international association for the study of lung cancer international staging committee and the international mesothelioma interest group. J Thorac Oncol 6(8):1304.12CrossRefPubMed
13.
Zurück zum Zitat Vigneswaran WT, Kircheva DY, Ananthanarayanan V, et al (2017) Amount of epithelioid differentiation is a predictor of survival in malignant pleural mesothelioma. Ann Thorac Surg 103(3):962–966CrossRefPubMed Vigneswaran WT, Kircheva DY, Ananthanarayanan V, et al (2017) Amount of epithelioid differentiation is a predictor of survival in malignant pleural mesothelioma. Ann Thorac Surg 103(3):962–966CrossRefPubMed
14.
Zurück zum Zitat Curran D, Sahmoud T, Therasse P, van Meerbeeck J, Postmus PE, Giaccone G (1998) Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol 16(145):52 Curran D, Sahmoud T, Therasse P, van Meerbeeck J, Postmus PE, Giaccone G (1998) Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol 16(145):52
15.
Zurück zum Zitat Merritt N, Blewett CJ, Miller JD, Bennett WF, Young JE, Urschel JD (2001) Survival after conservative (palliative) management of pleural malignant mesothelioma. J Surg Oncol 78:171–174CrossRefPubMed Merritt N, Blewett CJ, Miller JD, Bennett WF, Young JE, Urschel JD (2001) Survival after conservative (palliative) management of pleural malignant mesothelioma. J Surg Oncol 78:171–174CrossRefPubMed
16.
Zurück zum Zitat Vogelzang NJ, Rusthoven JJ, Symanowski J et al (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21:2636–2644CrossRefPubMed Vogelzang NJ, Rusthoven JJ, Symanowski J et al (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21:2636–2644CrossRefPubMed
17.
Zurück zum Zitat Rusch V, Baldini EH, Bueno R et al (2013) participants in 2012 International Mesothelioma Interest Group Congress. The role of surgical cytoreduction in the treatment of malignant pleural mesothelioma: meeting summary of the International Mesothelioma Interest Group Congress, September 11–14, 2012, Boston, MA. J Thorac Cardiovasc Surg 145:909–910CrossRefPubMed Rusch V, Baldini EH, Bueno R et al (2013) participants in 2012 International Mesothelioma Interest Group Congress. The role of surgical cytoreduction in the treatment of malignant pleural mesothelioma: meeting summary of the International Mesothelioma Interest Group Congress, September 11–14, 2012, Boston, MA. J Thorac Cardiovasc Surg 145:909–910CrossRefPubMed
18.
Zurück zum Zitat Sharkey AJ, Tenconi S, Nakas A, Waller DA (2016) The effects of an intentional transition from extrapleural pneumonectomy to extended pleurectomy/decortication. Eur J Cardiothorac Surg 49(6):1632–1641CrossRefPubMed Sharkey AJ, Tenconi S, Nakas A, Waller DA (2016) The effects of an intentional transition from extrapleural pneumonectomy to extended pleurectomy/decortication. Eur J Cardiothorac Surg 49(6):1632–1641CrossRefPubMed
19.
Zurück zum Zitat Kircheva DY, Husain AN, Watson S, Kindler HL, Durkin A, Vigneswaran WT (2016) Specimen weight and volume: important predictors of survival in malignant pleural mesothelioma. Eur J Cardiothorac Surg 49(6):1642–1647CrossRefPubMed Kircheva DY, Husain AN, Watson S, Kindler HL, Durkin A, Vigneswaran WT (2016) Specimen weight and volume: important predictors of survival in malignant pleural mesothelioma. Eur J Cardiothorac Surg 49(6):1642–1647CrossRefPubMed
Metadaten
Titel
Influence of Pleurectomy and Decortication in Health-Related Quality of Life Among Patients with Malignant Pleural Mesothelioma
verfasst von
Wickii T. Vigneswaran
Diana Y. Kircheva
Adrian E. Rodrigues
Sydeaka Watson
Amy Durkin Celauro
Berkley Rose
Hedy L. Kindler
Aliya N. Husain
Publikationsdatum
25.09.2017
Verlag
Springer International Publishing
Erschienen in
World Journal of Surgery / Ausgabe 4/2018
Print ISSN: 0364-2313
Elektronische ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-017-4264-4

Weitere Artikel der Ausgabe 4/2018

World Journal of Surgery 4/2018 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.